Virios Therapeutics (VIRI) Competitors $4.93 0.00 (0.00%) As of 06/10/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock VIRI vs. KMDA, PGEN, ITOS, RVNC, FULC, CKPT, VIGL, RZLT, ARCT, and ADCTShould you be buying Virios Therapeutics stock or one of its competitors? The main competitors of Virios Therapeutics include Kamada (KMDA), Precigen (PGEN), iTeos Therapeutics (ITOS), Revance Therapeutics (RVNC), Fulcrum Therapeutics (FULC), Checkpoint Therapeutics (CKPT), Vigil Neuroscience (VIGL), Rezolute (RZLT), Arcturus Therapeutics (ARCT), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry. Virios Therapeutics vs. Its Competitors Kamada Precigen iTeos Therapeutics Revance Therapeutics Fulcrum Therapeutics Checkpoint Therapeutics Vigil Neuroscience Rezolute Arcturus Therapeutics ADC Therapeutics Virios Therapeutics (NASDAQ:VIRI) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, media sentiment, institutional ownership, earnings, profitability, valuation and risk. Which has stronger valuation & earnings, VIRI or KMDA? Kamada has higher revenue and earnings than Virios Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirios TherapeuticsN/AN/A-$5.30M-$0.27-18.26Kamada$167.24M2.37$8.28M$0.2923.79 Do analysts prefer VIRI or KMDA? Virios Therapeutics currently has a consensus target price of $3.00, indicating a potential downside of 39.15%. Kamada has a consensus target price of $14.67, indicating a potential upside of 112.56%. Given Kamada's stronger consensus rating and higher possible upside, analysts clearly believe Kamada is more favorable than Virios Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Kamada 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is VIRI or KMDA more profitable? Kamada has a net margin of 9.92% compared to Virios Therapeutics' net margin of 0.00%. Kamada's return on equity of 6.30% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Virios TherapeuticsN/A -130.33% -115.00% Kamada 9.92%6.30%4.49% Does the MarketBeat Community believe in VIRI or KMDA? Kamada received 325 more outperform votes than Virios Therapeutics when rated by MarketBeat users. Likewise, 66.26% of users gave Kamada an outperform vote while only 50.00% of users gave Virios Therapeutics an outperform vote. CompanyUnderperformOutperformVirios TherapeuticsOutperform Votes350.00% Underperform Votes350.00% KamadaOutperform Votes32866.26% Underperform Votes16733.74% Does the media favor VIRI or KMDA? In the previous week, Kamada had 4 more articles in the media than Virios Therapeutics. MarketBeat recorded 4 mentions for Kamada and 0 mentions for Virios Therapeutics. Kamada's average media sentiment score of 0.34 beat Virios Therapeutics' score of 0.00 indicating that Kamada is being referred to more favorably in the news media. Company Overall Sentiment Virios Therapeutics Neutral Kamada Neutral Which has more risk and volatility, VIRI or KMDA? Virios Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Comparatively, Kamada has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Do insiders and institutionals have more ownership in VIRI or KMDA? 9.1% of Virios Therapeutics shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by company insiders. Comparatively, 36.1% of Kamada shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryKamada beats Virios Therapeutics on 16 of the 17 factors compared between the two stocks. Get Virios Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRI vs. The Competition Export to ExcelMetricVirios TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$94.94M$6.93B$5.60B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-18.268.8527.2320.02Price / SalesN/A256.44417.65154.33Price / CashN/A65.8538.2534.64Price / Book24.656.617.124.70Net Income-$5.30M$143.93M$3.23B$247.97M7 Day Performance-7.68%3.84%2.74%2.64%1 Month Performance8.11%11.14%8.94%6.39%1 Year Performance2,052.84%4.35%31.59%13.95% Virios Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRIVirios TherapeuticsN/A$4.93flat$3.00-39.1%+2,104.8%$94.94MN/A-18.265KMDAKamada3.8304 of 5 stars$6.90+0.7%$14.67+112.6%+36.3%$396.61M$167.24M24.64360Positive NewsShort Interest ↑PGENPrecigen4.1585 of 5 stars$1.33+0.8%$5.50+313.5%-8.5%$392.59M$4.20M-2.42190Analyst RevisionITOSiTeos Therapeutics3.8712 of 5 stars$10.01-0.1%$15.86+58.4%-38.7%$383.51M$35M-3.1890Insider TradeHigh Trading VolumeRVNCRevance Therapeutics2.5937 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500FULCFulcrum Therapeutics0.4646 of 5 stars$6.96+1.2%$6.29-9.7%-7.7%$375.69M$80M-22.45100Positive NewsAnalyst RevisionCKPTCheckpoint Therapeutics2.556 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210VIGLVigil Neuroscience4.0548 of 5 stars$7.93+0.5%$10.80+36.2%+71.6%$370.11MN/A-3.8540Positive NewsRZLTRezolute2.7383 of 5 stars$4.22+2.4%$12.14+187.7%-18.5%$360.89MN/A-3.4640Positive NewsHigh Trading VolumeARCTArcturus Therapeutics3.2664 of 5 stars$12.81+2.2%$53.50+317.6%-61.6%$347.42M$131.27M-5.77180News CoveragePositive NewsAnalyst RevisionADCTADC Therapeutics2.8524 of 5 stars$3.50+13.3%$7.75+121.3%+13.2%$347.32M$75.82M-1.47310News CoveragePositive NewsAnalyst RevisionGap UpHigh Trading Volume Related Companies and Tools Related Companies Kamada Alternatives Precigen Alternatives iTeos Therapeutics Alternatives Revance Therapeutics Alternatives Fulcrum Therapeutics Alternatives Checkpoint Therapeutics Alternatives Vigil Neuroscience Alternatives Rezolute Alternatives Arcturus Therapeutics Alternatives ADC Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIRI) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virios Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VIRI Stock Free VIRI Stock Alerts